BR112018010155A8 - segmentação do receptor formil-peptídeo 2/receptor lipoxina a4 (fpr2/alx) para tratamento de doença cardíaca - Google Patents
segmentação do receptor formil-peptídeo 2/receptor lipoxina a4 (fpr2/alx) para tratamento de doença cardíacaInfo
- Publication number
- BR112018010155A8 BR112018010155A8 BR112018010155A BR112018010155A BR112018010155A8 BR 112018010155 A8 BR112018010155 A8 BR 112018010155A8 BR 112018010155 A BR112018010155 A BR 112018010155A BR 112018010155 A BR112018010155 A BR 112018010155A BR 112018010155 A8 BR112018010155 A8 BR 112018010155A8
- Authority
- BR
- Brazil
- Prior art keywords
- receptor
- fpr2
- lipoxin
- alx
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562259498P | 2015-11-24 | 2015-11-24 | |
| PCT/US2016/063036 WO2017091496A1 (en) | 2015-11-24 | 2016-11-21 | Targeting of the formyl-peptide receptor 2/lipoxin a4 receptor (fpr2/alx) for treatment of heart disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112018010155A2 BR112018010155A2 (pt) | 2018-11-21 |
| BR112018010155A8 true BR112018010155A8 (pt) | 2019-02-26 |
Family
ID=57544530
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018010155A BR112018010155A8 (pt) | 2015-11-24 | 2016-11-21 | segmentação do receptor formil-peptídeo 2/receptor lipoxina a4 (fpr2/alx) para tratamento de doença cardíaca |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20180325869A1 (https=) |
| EP (1) | EP3380091A1 (https=) |
| JP (1) | JP2018538367A (https=) |
| KR (1) | KR20180081528A (https=) |
| CN (1) | CN108348479A (https=) |
| AU (1) | AU2016359463A1 (https=) |
| BR (1) | BR112018010155A8 (https=) |
| CA (1) | CA3006291A1 (https=) |
| EA (1) | EA201891007A1 (https=) |
| IL (1) | IL259468A (https=) |
| MX (1) | MX2018005756A (https=) |
| SG (1) | SG11201803816RA (https=) |
| WO (1) | WO2017091496A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6811241B2 (ja) | 2015-12-10 | 2021-01-13 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ピペリジノンホルミルペプチド受容体２およびホルミルペプチド受容体１アゴニスト |
| WO2018227065A1 (en) | 2017-06-09 | 2018-12-13 | Bristol-Myers Squibb Company | Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists |
| EP3634958B1 (en) * | 2017-06-09 | 2021-07-21 | Bristol-Myers Squibb Company | Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonists |
| KR102615099B1 (ko) | 2017-06-09 | 2023-12-15 | 브리스톨-마이어스 스큅 컴퍼니 | 아릴 헤테로시클릭 피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제 |
| KR102615095B1 (ko) * | 2017-06-09 | 2023-12-15 | 브리스톨-마이어스 스큅 컴퍼니 | 피페리디논 포르밀 펩티드 2 수용체 효능제 |
| KR102803660B1 (ko) | 2018-03-05 | 2025-05-02 | 브리스톨-마이어스 스큅 컴퍼니 | 페닐피롤리디논 포르밀 펩티드 2 수용체 효능제 |
| CN113166134B (zh) | 2018-11-26 | 2024-06-14 | 百时美施贵宝公司 | 作为甲酰肽2受体激动剂的吡咯烷酮衍生物 |
| CA3185263A1 (en) | 2020-07-09 | 2022-01-13 | James A. Johnson | Pyrazolone formyl peptide 2 receptor agonists |
| KR20230051525A (ko) | 2020-08-12 | 2023-04-18 | 브리스톨-마이어스 스큅 컴퍼니 | 옥소피롤리딘 우레아 fpr2 효능제 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101903378B (zh) * | 2007-12-18 | 2014-03-12 | 埃科特莱茵药品有限公司 | 氨基三唑衍生物 |
| CN103221392B (zh) * | 2010-11-17 | 2015-06-03 | 埃科特莱茵药品有限公司 | 桥联螺[2.4]庚酯衍生物 |
| CA2871334A1 (en) * | 2012-05-16 | 2013-11-21 | Actelion Pharmaceuticals Ltd | 1-(p-tolyl)cyclopropyl substituted bridged spiro[2.4]heptane derivatives as alx receptor agonists |
| JP6811241B2 (ja) * | 2015-12-10 | 2021-01-13 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ピペリジノンホルミルペプチド受容体２およびホルミルペプチド受容体１アゴニスト |
| KR102803660B1 (ko) * | 2018-03-05 | 2025-05-02 | 브리스톨-마이어스 스큅 컴퍼니 | 페닐피롤리디논 포르밀 펩티드 2 수용체 효능제 |
-
2016
- 2016-11-21 MX MX2018005756A patent/MX2018005756A/es unknown
- 2016-11-21 US US15/776,927 patent/US20180325869A1/en not_active Abandoned
- 2016-11-21 EA EA201891007A patent/EA201891007A1/ru unknown
- 2016-11-21 JP JP2018545568A patent/JP2018538367A/ja not_active Withdrawn
- 2016-11-21 SG SG11201803816RA patent/SG11201803816RA/en unknown
- 2016-11-21 AU AU2016359463A patent/AU2016359463A1/en not_active Abandoned
- 2016-11-21 CA CA3006291A patent/CA3006291A1/en not_active Abandoned
- 2016-11-21 CN CN201680068442.7A patent/CN108348479A/zh active Pending
- 2016-11-21 WO PCT/US2016/063036 patent/WO2017091496A1/en not_active Ceased
- 2016-11-21 KR KR1020187014477A patent/KR20180081528A/ko not_active Withdrawn
- 2016-11-21 BR BR112018010155A patent/BR112018010155A8/pt not_active Application Discontinuation
- 2016-11-21 EP EP16810536.9A patent/EP3380091A1/en not_active Withdrawn
-
2018
- 2018-05-17 IL IL259468A patent/IL259468A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2018538367A (ja) | 2018-12-27 |
| US20180325869A1 (en) | 2018-11-15 |
| WO2017091496A1 (en) | 2017-06-01 |
| CA3006291A1 (en) | 2017-06-01 |
| BR112018010155A2 (pt) | 2018-11-21 |
| EA201891007A1 (ru) | 2018-11-30 |
| KR20180081528A (ko) | 2018-07-16 |
| MX2018005756A (es) | 2018-08-01 |
| SG11201803816RA (en) | 2018-06-28 |
| AU2016359463A1 (en) | 2018-07-12 |
| CN108348479A (zh) | 2018-07-31 |
| EP3380091A1 (en) | 2018-10-03 |
| IL259468A (en) | 2018-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018010155A8 (pt) | segmentação do receptor formil-peptídeo 2/receptor lipoxina a4 (fpr2/alx) para tratamento de doença cardíaca | |
| UY35548A (es) | Péptidos terapéuticos para el tratamiento de trastornos metabólicos. | |
| BR112021024236A2 (pt) | Proteínas multiespecíficas | |
| CL2020001495A1 (es) | Composiciones y método para el tratamiento de enfermedades metabólicas | |
| MX384908B (es) | Rad1901 para usarse en el tratamiento de cáncer en sujetos con cáncer positivo a receptor de estrógeno alfa resistente a farmaco. | |
| MX392374B (es) | Peptidos terapeuticos relacionados con mots-c. | |
| SA518391624B1 (ar) | Ror- منظمات جاما | |
| MX2018008557A (es) | Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos. | |
| DOP2017000097A (es) | Composiciones y métodos de uso para tratar trastornos metabólicos | |
| UY37594A (es) | Biomarcador inmunologico para predecir el efecto clinico de inmunoterapia del cancer | |
| CY1124243T1 (el) | Αναστολη του ιοντικου διαυλου υποδοχεα παροδικου δυναμικου α1 | |
| CL2018000597A1 (es) | Métodos para tratar enfermedades inflamatorias | |
| BR112017012381A2 (pt) | imunoterapia para doença angiogênica | |
| CO2017000346A2 (es) | Anticuerpos de unión a protofibrillas aβ | |
| EA033250B1 (ru) | Пирролидиновые модуляторы gpr40 для лечения расстройств, таких как диабет | |
| CL2020000812A1 (es) | Semaglutida en la terapia médica. | |
| MX2019007161A (es) | Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta. | |
| BR112016020260A8 (pt) | uso de um composto na fabricação de um medicamento para tratar uma doença colestática intra-hepática | |
| AR104755A1 (es) | Método para el tratamiento de enfermedad neurológica | |
| BR112018001424A2 (pt) | compostos, composição farmacêutica e métodos para o tratamento de uma doença neoplásica, para o tratamento de um distúrbio inflamatório ou distúrbio autoimune, para o tratamento de uma doença neurodegenerativa e para o tratamento de um distúrbio metabólico | |
| SI3565592T1 (sl) | Zdravljenje presnovnih bolezni z zaviranjem aktivacije miostatina | |
| MX2017016346A (es) | Metodos de tratamiento con taselisib. | |
| MX2018001592A (es) | Composiciones y metodos para el tratamiento y la prevencion de trastornos neurodegenerativos. | |
| BR112017009358A2 (pt) | imunoterapia específica de peptídeo t terapêutico para uso no tratamento de metástase cerebral de um paciente com hla-2 positivo | |
| MX2021006865A (es) | Anticuerpos anti-alfa-sinucleina y usos de estos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |